Novo Nordisk Region Aameo And Latam A/S

Ledelsesberetning

Financial key figures 2024 2023 2022 2021 2020DKK '000 DKK '000 DKK '000 DKK '000 DKK '000Income statement:Operating profit/(loss) (227) (223) (238) (163) (201) Net financials & profit/(loss) in subsidiaries 3,511,287 3,099,881 388,903 2,815,602 1,304,356 Net profit/(loss) for the year 3,490,408 3,085,091 378,311 2,805,906 1,301,989 Balance sheet:Financial assets 23,539,459 17,776,676 15,838,068 15,259,177 10,183,700 Total assets 23,702,511 17,902,805 15,972,436 15,705,091 10,330,950 Equity 22,790,262 17,082,319 14,998,627 15,166,557 9,678,982 Development during the financial yearNet profit for Novo Nordisk Region AAMEO and LATAM A/S ended at DKK 3,490,408 thousand for the year 2024 compared with DKK 3,085,091 thousand for the year 2023.The net profit is in line with the expectations stated in the Annual Report 2023.Outlook for the company, including specific assumptions and elements of uncertaintyLike in previous years the company's most important activity is the holding of equity investments in a portfolio of subsidiaries.The company's financial performance reflects the development in the underlying subsidiaries. Management expects to record a similar return in 2025 compared with 2024.Novo Nordisk Region AAMEO and LATAM A/S holds affiliates in Ukraine and Russia. The conflict between the two countries can have a negative impact on the income in the two affiliates, but the potential impact is not considered significant for the company, and there has not been provided for the potential impact from this.

Beskrivelse af virksomhedens væsentligste aktiviteter

Main activitiesThe company's main activities are the holding of equity investments in companies, and other investments, as well as financial activities, and – at the discretion of the Board of Directors – supporting the operations of such companies.